Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

AML1-ETO Collaborates with the TALE Homeobox Genes MEIS1 and MEIS2 in Inducing AML.

Naidu M Vegi, PhD, Josef Klappacher, MSc, Franz Oswald, PhD, Rainer Claus, MD, Medhanie M Mulaw, PhD, Verena Thiel, Msc, Vijay P.S Rawat, PhD, Leticia Quintanilla Fend, MD, Christoph Plass, PhD, Konstanze Döhner, MD, Hartmut Döhner, MD, Wolfgang Hiddemann, MD, Michaela Feuring Buske, MD, Christian Buske, MD

Blood (2012) 120 (21): 2387.

https://doi.org/10.1182/blood.V120.21.2387.2387

Published: 2012

Journal Articles

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

Blood (2012) 120 (21): 2840.

https://doi.org/10.1182/blood.V120.21.2840.2840

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in “Open Seas” and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML)

Ying Qu, MD, M.Sc, Andreas Lennartsson, PhD, Verena I. Gaidzik, MD, Ph.D, Stefan Deneberg, MD, Ph.D, Sofia Bengtzén, Mohsen Karimi Arzenani, PhD, Lars Bullinger, MD, PhD, Konstanze Döhner, MD, Ph.D, Sören Lehmann, MD, PhD

Blood (2012) 120 (21): 653.

https://doi.org/10.1182/blood.V120.21.653.653

Published: 2012

Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 710.

https://doi.org/10.1182/blood.V120.21.710.710

Published: 2012

Journal Articles

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, MD, Ph.D, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, Jochen Greiner, MD

Blood (2012) 120 (21): 3592.

https://doi.org/10.1182/blood.V120.21.3592.3592

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia

Blood (2011) 118 (21): 55.

https://doi.org/10.1182/blood.V118.21.55.55

Published: 2011

Journal Articles

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Michael Lübbert, Claudia Schmoor, Anne Hagemeijer, Björn Hackanson, Rainer Claus, Björn Rüter, Mathias Schmid, Ulrich Germing, MD, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Konstanze Döhner, Hartmut Döhner

Blood (2011) 118 (21): 2609.

https://doi.org/10.1182/blood.V118.21.2609.2609

Published: 2011

Journal Articles

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Jochen Greiner, MD, Yoko Ono, Susanne Hofmann, Vanessa Schneider, Anita Schmitt, Lu Zhang, Elmar Mehring, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, MD, PhD

Blood (2011) 118 (21): 2569.

https://doi.org/10.1182/blood.V118.21.2569.2569

Published: 2011

Journal Articles

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Jan Krönke, Lars Bullinger, Frank G. Rücker, Verena I. Gaidzik, MD, Michael WM Kühn, Karin Bezet, Veronica Teleanu, Peter Paschka, MD, Daniela Späth, Thomas Kindler, MD, Helmut R. Salih, MD, Jürgen Krauter, MD, Arnold Ganser, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner

Blood (2011) 118 (21): 237.

https://doi.org/10.1182/blood.V118.21.237.237

Published: 2011

Journal Articles

Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia

Anna Dolnik, Julia C Engelmann, Maren Scharfenberger-Schmeer, Frank G Rücker, Jan Krönke, Michael WM Kühn, Peter Paschka, MD, Verena I. Gaidzik, MD, Sabine Kayser, Richard F. Schlenk, MD, Berit Haldemann, Stephan Wolf, Hartmut Döhner, MD, Claudio Lottaz, Konstanze Döhner, MD, Lars Bullinger

Blood (2011) 118 (21): 402.

https://doi.org/10.1182/blood.V118.21.402.402

Published: 2011

Journal Articles

Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,

Michael W.M. Kühn, MD, Lars Bullinger, Jennifer Edelmann, MD, Jan Krönke, MD, Gröschel Stefan, MD, Frank G. Rücker, Peter Paschka, MD, Verena I. Gaidzik, MD, Karlheinz Holzmann, PhD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2011) 118 (21): 3546.

https://doi.org/10.1182/blood.V118.21.3546.3546

Published: 2011

Journal Articles

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Blood (2011) 118 (21): 3558.

https://doi.org/10.1182/blood.V118.21.3558.3558

Published: 2011

Journal Articles

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Blood (2011) 118 (21): 80.

https://doi.org/10.1182/blood.V118.21.80.80

Published: 2011

Journal Articles

Genetic and Epigenetic Profiling on 7q22 Identifies ATXN7L1 As Candidate Tumor Suppressor in Acute Myelogenous Leukemia

Anna R Poetsch, Rainer Claus, Jacques Bonnet, Didier Devys, Frank G. Rücker, László Tora, Konstanze Döhner, MD, Hartmut Döhner, MD, Christoph Plass

Blood (2011) 118 (21): 1408.

https://doi.org/10.1182/blood.V118.21.1408.1408

Published: 2011

Journal Articles

Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPARγ Signaling

Katrin Faber, Lars Bullinger, Angela Garding, Daniel Mertens, Daniela Martin, Daniel Walcher, Konstanze Döhner, Hartmut Döhner, MD, Stephen M. Sykes, Rainer Claus, Christoph Plass, Steven W. Lane, Claudia Scholl, Stefan Fröhling

Blood (2011) 118 (21): 1355.

https://doi.org/10.1182/blood.V118.21.1355.1355

Published: 2011

Journal Articles

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Peter Paschka, MD, Anja Stölzle, Andrea Corbacioglu, PhD, David Nachbaur, MD, Thomas Kindler, MD, Alexander C. Burchardt, MD, Helmut R. Salih, MD, Hans-Günther Mergenthaler, MD, Hans J. Salwender, MD, Daniela Späth, MSc, Lars Bullinger, Juergen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2011) 118 (21): 415.

https://doi.org/10.1182/blood.V118.21.415.415

Published: 2011

NARROW

AML1-ETO Collaborates with the TALE Homeobox Genes MEIS1 and MEIS2 in Inducing AML.

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in “Open Seas” and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML)

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia

Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Genetic and Epigenetic Profiling on 7q22 Identifies ATXN7L1 As Candidate Tumor Suppressor in Acute Myelogenous Leukemia

Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPARγ Signaling

DNMT3A mutations Predict for Inferior Outcome in NPM1 -Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only